枸橼酸抗凝在肝衰竭患者进行人工肝血液净化治疗的安全性
Safety of Citrate Anticoagulation in Patients with Liver Failure Undergoing Artificial Liver Hemodialysis
DOI: 10.12677/ACM.2023.133634, PDF,   
作者: 袁占渝, 张 丽*：新疆医科大学第一附属医院，新疆 乌鲁木齐
关键词: 肝衰竭；人工肝；枸橼酸；Liver Failure； Artificial Liver； Citric Acid
摘要: 肝功能衰竭仍缺乏有效的治疗方法，人工肝是当前治疗主流形式；人工肝支持系统过程中必然涉及到体外循环，抗凝是其顺利进行的重要保证。目前枸橼酸抗凝因其诸多优势受到关注，当前，有关文献报道其在肝衰竭患者中安全运用，这预示着今后枸橼酸抗凝在肝衰竭中运用的普遍性。
Abstract: There is still a lack of effective treatment for liver failure, artificial liver is the mainstream form of current treatment; extracorporeal circulation must be involved in the process of artificial liver support system, and anticoagulation is an important guarantee for its smooth progress. At present, citrate anticoagulation has received attention because of its many advantages. At present, it is re-ported in the relevant literature that it is safely used in patients with liver failure, which indicates the universality of citrate anticoagulation in liver failure in the future.
文章引用：袁占渝, 张丽. 枸橼酸抗凝在肝衰竭患者进行人工肝血液净化治疗的安全性[J]. 临床医学进展, 2023, 13(3): 4427-4430. https://doi.org/10.12677/ACM.2023.133634

参考文献

[1] 陈佳佳, 范林骁, 李兰娟. 《肝衰竭诊治指南(2018版)》指南解读[J]. 中国临床医生杂志, 2020, 48(11): 1279-1282.
[2] Rademacher, S., Oppert, M. and Jörres, A. (2011) Artificial Extracorporeal Liver Support Therapy in Patients with Severe Liver Failure. Expert Review of Gastroenterology & Hepatology, 5, 591-599. [Google Scholar] [CrossRef] [PubMed]
[3] 邹龙, 等. 非生物型人工肝的治疗新进展[J]. 中国普外基础与临床杂志, 2017, 24(5): 634-637.
[4] Di Campli, C., et al. (2005) Catholic University Experience with Molecular Adsorbent Recycling System in Patients with Severe Liver Failure. Transplantation Proceedings, 37, 2547-2550. [Google Scholar] [CrossRef] [PubMed]
[5] Kutsogiannis, D.J., et al. (2000) Regional Citrate Antico-agulation in Continuous Venovenous Hemodiafiltration. American Journal of Kidney Diseases, 35, 802-811. [Google Scholar] [CrossRef] 
[6] Morita, Y., et al. (1961) Regional Anticoagulation during Hemodialysis Using Citrate. The American Journal of the Medical Sciences, 242, 32-43. [Google Scholar] [CrossRef] [PubMed]
[7] Palsson, R. and Niles, J.L. (1999) Regional Citrate An-ticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients with a High Risk of Bleeding. Kidney International, 55, 1991-1997. [Google Scholar] [CrossRef] [PubMed]
[8] Chappell, J.B. (1964) The Oxidation of Citrate, Isocitrate and Cis-Aconitate by Isolated Mitochondria. Biochemical Journal, 90, 225-237. [Google Scholar] [CrossRef] [PubMed]
[9] 龚德华. 枸橼酸三钠抗凝在血液净化中的应用[J]. 肾脏病与透析肾移植杂志, 2003(3): 286-289.
[10] 乐伟波, 龚德华. 枸橼酸的代谢动力学及其在连续性血液净化中的应用[J]. 肾脏病与透析肾移植杂志, 2009, 18(4): 363-366.
[11] Shum, H.P., Yan, W.W. and Chan, T.M. (2014) Risks and Benefits of Citrate Anticoagulation for Continuous Renal Replacement Therapy. Hong Kong Medical Journal, 21, 149-154. [Google Scholar] [CrossRef] [PubMed]
[12] Khwaja, A. (2012) KDIGO Clinical Practice Guidelines for Acute Kid-ney Injury. Nephron Clinical Practice, 120, c179-c184. [Google Scholar] [CrossRef] [PubMed]
[13] Tolwani, A. and Wille, K.M. (2012) Advances in Continuous Renal Replacement Therapy: Citrate Anticoagulation Update. Blood Purifi-cation, 34, 88-93. [Google Scholar] [CrossRef] [PubMed]
[14] Slowinski, T., et al. (2015) Safety and Efficacy of Re-gional Citrate Anticoagulation in Continuous Venovenous Hemodialysis in the Presence of Liver Failure: The Liver Cit-rate Anticoagulation Threshold (L-CAT) Observational Study. Critical Care, 19, 349. [Google Scholar] [CrossRef] [PubMed]
[15] Qin, G., et al. (2014) Artificial Liver Support System Improves Short- and Long-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Single-Center Experience. Medicine (Baltimore), 93, e338. [Google Scholar] [CrossRef] 
[16] Larsen, F.S., et al. (2016) High-Volume Plasma Exchange in Patients with Acute Liver Failure: An Open Randomised Controlled Trial. Journal of Hepatology, 64, 69-78. [Google Scholar] [CrossRef] [PubMed]
[17] Honore, P.M., et al. (2020) In Severe Liver Disease, Citrate Can Be Used Safely: The Question Remains—by Which Mechanism. Critical Care, 24, Article No. 63. [Google Scholar] [CrossRef] [PubMed]
[18] Honore, P.M., et al. (2019) Inducible Metabolic Pathway for Cit-rate Metabolism in Case of Major Liver Dysfunction: Fact or Fiction? Critical Care, 23, Article No. 166. [Google Scholar] [CrossRef] [PubMed]
[19] Sık, G., et al. (2020) Regional Citrate versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Children. The International Journal of Artifi-cial Organs, 43, 234-241. [Google Scholar] [CrossRef] [PubMed]
[20] Lahmer, T., et al. (2015) Sustained Low-Efficiency Dialysis with Regional Citrate Anticoagulation in Medical Intensive Care Unit Patients with Liver Failure: A Prospective Study. Jour-nal of Critical Care, 30, 1096-1100. [Google Scholar] [CrossRef] [PubMed]
[21] 单楠楠. 分析局部枸橼酸钠抗凝技术在重症监护病房(ICU)肝功能障碍患者连续静脉-静脉血液滤过(CVVH)中的安全性、有效性[J]. 中国医药指南, 2020, 18(16): 69-71.
[22] 章颖, 明芳, 薛红. 局部枸橼酸抗凝在肝衰竭患者连续性静脉-静脉血液滤过治疗中的应用[J]. 交通医学, 2021, 35(4): 380-383.
[23] 王临旭, 等. 局部枸橼酸抗凝在DPMAS联合低置换量血浆置换治疗慢加急性肝衰竭患者中的应用[J]. 现代生物医学进展, 2021, 21(14): 2748-2752, 2800.
[24] Ma, Y., et al. (2019) Safety and Efficacy of Regional Citrate Anticoagulation during Plasma Adsorption plus Plasma Exchange Therapy for Patients with Acute-on-Chronic Liver Failure: A Pilot Study. Blood Purification, 48, 223-232. [Google Scholar] [CrossRef] [PubMed]
[25] 中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版) [J]. 临床肝胆病杂志, 2022, 38(4): 767-775.

为你推荐